[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prositron-emission-tomography\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prositron-emission-tomography":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100537388","68ga-tcr-fapi-petct-guided-precision-surgery-for-mtc-100537388",false,"NCT06277180","68Ga-TCR-FAPI PET\u002FCT Guided Precision Surgery for MTC","Evaluating the Clinical Value of 68Ga-TCR-FAPI PET\u002FCT to Guide the Surgical Treatment for Medullary Thyroid Carcinoma (MTC)","Inclusion Criteria:\n\n* Age between 18 and 75 years；\n* Diagnosed with MTC and have surgical indication based on preliminary evaluation; the tumor may be newly diagnosed or previously treated;\n* Expected survival of at least 12 weeks;\n* No major organ dysfunction (heart, lung, liver, kidney and other major organ include), acute or life-threatening status of infection;\n* Be willing and able to understand the research content and provide written informed consent\u002Fassent for the trial.\n\nExclusion Criteria:\n\n* Have a history of imaging agent allergies;\n* Does not meet the PET-CT scan sedation requirements, or has contraindications for PET-CT examination;\n* Be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial;\n* No surgical indication (i.e., no measurable disease, unresectable disease, or significant present of distant metastasis), refusing surgery or 68Ga-TCR-FAPI PET\u002FCT-guided surgery.","ALL","18 Years","75 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET\u002FCT to guide the surgical treatment of medullary thyroid carcinoma (MTC). The surgical extent of MTC is determined based on the lesion range revealed by 68Ga-TCR-FAPI PET\u002FCT, with the main endpoint being 1-month post-surgical calcitonin level.",[27,28,29,30],"Medullary Thyroid Cancer","Prositron Emission Tomography","Fibroblast Activation Protein Inhibitor","Surgery",[27,28,29,30],"RECRUITING","2024-02-18",{"date":35,"type":36},"2024-02-26","ACTUAL",{"date":38,"type":36},"2023-10-01",{"date":40,"type":21},"2027-12-31",{"name":42,"class":43},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER"]